With a market capitalization (market cap) of $1.12B — a measure of how much the company is worth — LB Pharmaceuticals Inc Common Stock ranks #2,442 among the 2,529 companies tracked, and 341st in Healthcare as of September 24, 2026. Shares trade at $39.19, down 8.20% on the day.
of 2,529 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation September 23, 2026. Ranking headline cap is the snapshot figure as of September 24, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Sep 23, 2026 | $1.18B | +87.87% | $39.19 |
| 2025 | Dec 31, 2025 | $628.66M | — | $22.26 |
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Ranking figure $1.12B as of September 24, 2026.
LB Pharmaceuticals Inc Common Stock's ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $39.19 as of September 23, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $1.18B on September 23, 2026. See how the ranking works.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 25,299,372 shares. That figure is an average for the year, not the live count in the market-cap formula.
Multiplying the latest price by those FY 2025 weighted-average shares would give about $991.48M. The ranking uses the provider's reported market cap instead, which reflects a current share count rather than that annual average.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Undefined when revenue is zero
Undefined when revenue is zero
Undefined when revenue is zero
FY 2025
FY 2025
Undefined when revenue is zero
FY 2025
Undefined when revenue is zero
FY 2025
FY 2025
FY 2025
FY 2025
Not in this snapshot
FY 2025 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #14 | Eli Lilly and Company LLY | $1.09T | -1.49% |
| #21 | Johnson & Johnson JNJ | $648.67B | -0.01% |
| #24 |
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of September 24, 2026, LB Pharmaceuticals Inc Common Stock (LBRX) is worth $1.12B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, LB Pharmaceuticals Inc Common Stock’s book equity is about $301.31M. Market cap is the market value of the outstanding shares. As of September 24, 2026, its market cap is $1.12B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
LB Pharmaceuticals Inc Common Stock ranks #2,442 among the 2,529 companies tracked on MarketCapLens. In Healthcare it ranks #341 of 359.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
Too little price history
Over the past year, market cap and share price moved by different amounts. Share count can change independently of price. What changes market cap.
Not in this snapshot
FY 2025
| $468.73B |
| +0.03% |
| #35 | Merck & Co., Inc. MRK | $365.81B | -1.86% |
| #40 | UnitedHealth Group Incorporated UNH | $337.18B | -0.45% |
| #49 | Novartis AG NVS | $271.25B | +1.01% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #2439 | Universal Technical Institute, Inc. UTI | $1.12B | +0.05% |
| #2440 | McEwen Mining Inc. MUX | $1.12B | -6.32% |
| #2441 | Amerant Bancorp Inc. AMTB | $1.12B | -1.71% |
| #2443 | Tennant Company TNC | $1.12B | -1.15% |
| #2444 | Tandem Diabetes Care, Inc. TNDM | $1.12B | -6.40% |
| #2445 | Mission Produce, Inc. AVO | $1.12B | +0.32% |
LB Pharmaceuticals Inc Common Stock’s ranking market cap of $1.12B comes from the same snapshot as the rest of this site, as of September 24, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 25,299,372. The historical market-cap series last observed $1.18B on September 23, 2026.
Over the past year, LB Pharmaceuticals Inc Common Stock’s market cap is up 213.32%, using historical market-cap records rather than today’s share count applied to past prices.
LB Pharmaceuticals Inc Common Stock (LBRX) shares trade at $39.19, down 8.20% on the day, as of September 24, 2026.
Live P/E is share price divided by annual earnings per share. Sales-based ratios such as price/sales and operating margin are also blank when revenue is zero — not a 0× multiple.